HC Wainwright reissued their buy rating on shares of Verona Pharma (NASDAQ:VRNA – Free Report) in a research report released on Monday, Benzinga reports. The firm currently has a $32.00 price target on the stock.
Separately, Wedbush restated an outperform rating and set a $33.00 price objective on shares of Verona Pharma in a research report on Friday.
Get Our Latest Stock Report on Verona Pharma
Verona Pharma Trading Down 5.0 %
Institutional Inflows and Outflows
Several institutional investors have recently added to or reduced their stakes in the business. Campbell & CO Investment Adviser LLC raised its position in Verona Pharma by 1.7% in the fourth quarter. Campbell & CO Investment Adviser LLC now owns 50,836 shares of the company’s stock worth $1,011,000 after acquiring an additional 862 shares during the period. D.A. Davidson & CO. raised its position in shares of Verona Pharma by 2.8% during the 4th quarter. D.A. Davidson & CO. now owns 33,400 shares of the company’s stock valued at $664,000 after purchasing an additional 900 shares during the period. BNP Paribas Financial Markets raised its position in shares of Verona Pharma by 125.3% during the 4th quarter. BNP Paribas Financial Markets now owns 2,028 shares of the company’s stock valued at $40,000 after purchasing an additional 1,128 shares during the period. Geode Capital Management LLC raised its position in shares of Verona Pharma by 3.6% during the 1st quarter. Geode Capital Management LLC now owns 32,790 shares of the company’s stock valued at $658,000 after purchasing an additional 1,136 shares during the period. Finally, UBS Group AG raised its position in shares of Verona Pharma by 30.3% during the 1st quarter. UBS Group AG now owns 5,432 shares of the company’s stock valued at $109,000 after purchasing an additional 1,263 shares during the period. 9.89% of the stock is currently owned by institutional investors.
About Verona Pharma
Verona Pharma plc, a clinical stage biopharmaceutical company, focuses on development and commercialization of therapies for the treatment of respiratory diseases with unmet medical needs. The company's product candidate is ensifentrine, an inhaled and dual inhibitor of the phosphodiesterase (PDE) 3 and PDE4 enzymes that acts as both a bronchodilator and an anti-inflammatory agent in a single compound, which is in Phase 3 clinical trials for the treatment of chronic obstructive pulmonary disease, asthma, and cystic fibrosis.
Further Reading
- Five stocks we like better than Verona Pharma
- How Can Investors Benefit From After-Hours Trading
- Lemonade Stock: Unusual Call Volume Highlights Sweet Trade
- Dividend Capture Strategy: What You Need to Know
- Is UnitedHealth Group Stock a Strong Buy or a Falling Knife?
- What Are Growth Stocks and Investing in Them
- Cathie Wood Likes UiPath Stock Over NVDA, Should You?
Receive News & Ratings for Verona Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Verona Pharma and related companies with MarketBeat.com's FREE daily email newsletter.